These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1372625)

  • 21. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
    Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
    J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.
    Modi NB; Fox NL; Clow FW; Tanswell P; Cannon CP; Van de Werf F; Braunwald E
    J Clin Pharmacol; 2000 May; 40(5):508-15. PubMed ID: 10806604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction.
    Weaver WD
    Eur Heart J; 1996 Sep; 17 Suppl E():14-20. PubMed ID: 11823998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
    Dunn CJ; Goa KL
    Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers.
    Martin U; von Möllendorff E; Akpan W; Kientsch-Engel R; Kaufmann B; Neugebauer G
    Thromb Haemost; 1991 Nov; 66(5):569-74. PubMed ID: 1725068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.
    Cannon CP; McCabe CH; Gibson CM; Ghali M; Sequeira RF; McKendall GR; Breed J; Modi NB; Fox NL; Tracy RP; Love TW; Braunwald E
    Circulation; 1997 Jan; 95(2):351-6. PubMed ID: 9008448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of human recombinant tissue-type plasminogen activator on clinical and laboratory parameters of hemostasis and systemic plasminogen activation in the dog and the rat.
    Bloom JC; Sellers TS; Gries GC; Wheeldon EB; O'Brien SR; Lewis HB
    Thromb Haemost; 1988 Oct; 60(2):271-9. PubMed ID: 3146143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction.
    Koster RW; Cohen AF; Kluft C; Kasper FJ; van der Wouw PA; Weatherley BC
    Clin Pharmacol Ther; 1991 Sep; 50(3):267-77. PubMed ID: 1914361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Henkin J
    Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
    Arnold AE; Brower RW; Collen D; van Es GA; Lubsen J; Serruys PW; Simoons ML; Verstraete M
    J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction.
    Stangl K; Laule M; Tenckhoff B; Stangl V; Gliech V; Dübel P; Grohmann A; Melzer C; Langel J; Wernecke KD; Baumann G; Ziemer S
    Am J Cardiol; 1998 Apr; 81(7):841-7. PubMed ID: 9555772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin.
    Hoffmeister HM; Szabo S; Kastner C; Beyer ME; Helber U; Kazmaier S; Wendel HP; Heller W; Seipel L
    Circulation; 1998 Dec; 98(23):2527-33. PubMed ID: 9843458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction.
    Khan MI; Hackett DR; Andreotti F; Davies GJ; Regan T; Haider AW; McFadden E; Halson P; Maseri A
    Am J Cardiol; 1990 May; 65(16):1051-6. PubMed ID: 2109926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens.
    Eppler S; Senn T; Gilkerson E; Modi NB
    Biopharm Drug Dispos; 1998 Jan; 19(1):31-8. PubMed ID: 9510983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can we improve on front-loaded alteplase (r-TPA)?
    Aylward P
    Aust N Z J Med; 1998 Aug; 28(4):511-3. PubMed ID: 9777130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombolysis using consecutive high dose bolus and infusion of alteplase in a patient with acute massive pulmonary embolism.
    Tebbe U; Seifried E; Carlsson J; Tanswell P
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):475-80. PubMed ID: 1420824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. Thrombolysis in Myocardial Infarction in Korea (TIMIKO) study group.
    Park SJ
    Am J Cardiol; 1998 Sep; 82(6):811-3, A10. PubMed ID: 9761098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction.
    Gemmill JD; Hogg KJ; MacIntyre PD; Booth N; Rae AP; Dunn FG; Hillis WS
    Br Heart J; 1991 Aug; 66(2):134-8. PubMed ID: 1909151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.